Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from medicaid to medicare part d drug coverage

Medical Care

Volumn 52, Issue 8, 2014, Pages 695-703

  Adams, Alyce S ^a   Madden, Jeanne M ^b   Zhang, Fang ^b   Soumerai, Stephen B ^a   Gilden, Dan ^c   Griggs, Jennifer ^d   Trinacty, Connie M ^e   Bishop, Christine ^f   Ross Degnan, Dennis ^b  

^a DIVISION OF RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JEN Associates Inc   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e KAISER PERMANENTE   (United States)

^f BRANDEIS UNIVERSITY   (United States)

Author keywords

diabetes; dual enrollees; lipid lowering medications; Medicare Part D; racial disparities

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRIORITY JOURNAL; RACE DIFFERENCE; TIME SERIES ANALYSIS;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; COMORBIDITY; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MEDICAID; MEDICARE PART D; MEDICATION ADHERENCE; MIDDLE AGED; POLYPHARMACY; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84904554254     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000159     Document Type: Article

References (41)

1. Medicare Payment Advisory Commission. Chapter 3: Dual Eligible Beneficiaries: An Overview. 2004. Available at: http://www.medpac.gov/ publications/congressional-reports/June04-Ch3.pdf. Accessed August 15, 2013.
2. The Henry J. Kaiser Family Foundation. Dual Eligibles: Medicaids Role for Low-Income Medicare Beneficiaries. 2005. Available at: http:// kaiserfamilyfoundation.files.wordpress.com/2013/01/dual-eligibles-medicaids- role-for-low-income-medicare-beneficiaries-fact-sheet.pdf. Accessed May 15, 2015.
3. Jiang HJ, Wier LM, Potter DEB, et al. Potentially Preventable Hospitalizations among Medicare-Medicaid Dual Eligibles, 2008: Statistical Brief #96. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US). 2010.
4. Howard DL, Hakeem FB, Njue C, et al. Racially disproportionate admission rates for ambulatory care sensitive conditions in North Carolina. Public Health Rep. 2007;122:362-372.
5. Jiang HJ, Andrews R, Stryer D, et al. Racial/ethnic disparities in potentially preventable readmissions: the case of diabetes. Am J Public Health. 2005;95:1561-1567.
6. American Diabetes Association. Standards of medical care for diabetes-2013. Diabetes Care. 2013;36(suppl 1):S11-S66.
7. Blackwell S, Baugh D, Montgomery M, et al. Noncompliance in the use of cardiovascular medications in the Medicare Part D population. MMRR. 2011;1:E1-E27.
8. Schore J, Brown R, Lavin B. Racial disparities in prescription drug use among dually eligible beneficiaries. Health Care Financ Rev. 2003; 25:77-90.
9. Mark TL, Axelsen KJ, Mucha L, et al. Racial differences in switching, augmentation, and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. Am J Manag Care. 2007;S72-S79.
10. Margolis KL, Dunn K, Simpson LM, et al. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial (ALLHATLLT). Am Heart J. 2009;158:948-955.
11. Kochanek KD, Xu J, Murphy SL, et al. Deaths: Final Data for 2009. National Vital Statistics Reports. US Department of Health and Human Services: Hyattsville, MD; 2011. 60(3).
12. Choudhry NK, Patrick AR, Antman EM, et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117: 1261-1268.
13. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62:76-87.
14. Crowley J, Ashner D, Elam L. State Outpatient Prescription Drug Policies: Findings From a National Survey, 2005 Update. Prepared by Health Policy Institute at Georgetown University and Kaiser Commission on Medicaid and the Uninsured for the Henry J. Kaiser Family Foundation. Washington, DC: The Henry J. Kaiser Family Foundation; 2005. Available at: http://kaiserfamilyfoundation. files.wordpress.com/2013/01/state-medicaid-outpatient-prescription-drug- policies-findings-froma-national-survey-2005-update-report.pdf. Accessed September 11, 2007.
15. National Pharmaceutical Council. Pharmaceutical Benefits Under State Medical Assistance Programs, 2007. Available at: http://www.npcnow. org/Public/Research-Publications /Publications/pub-rel-research/pub-medicaid /Pharmaceutical-Benefits-Under-State-Medical-Assistance-Programs-2007.aspx. Accessed October 28, 2008.
16. Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients: effect on cost, therapy and out-of-pocket expenditures. Med Care. 1996;24:686-701.
17. Oklahoma Health Care Authority. Information for Providers. Available at: http://okhca.org/providers.aspx?id = 1218. Accessed October 28, 2011.
18. Hearne J. CRS Report for Congress: Prescription Drug Coverage Under Medicaid, Updated February 6, 2008. Prepared by Congressional Research Service for Members and Committees of Congress. Available at: http://aging.senate.gov/ crs/medicaid16.pdf. Accessed May 1, 2013.
19. Soumerai SB, Avorn J, Ross-Degnan D, et al. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550-556.
20. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drugpayment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
21. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;650-655.
22. The Henry J. Kaiser Family Foundation. Implications of the New Medicare Law for Dual Eligibles: 10 Key Questions and Answers. 2004. Available at: http://kaiserfamilyfoundation.files.wordpress.com/2013/01/implications-of-the- new-medicare-law-for-dual-eligibles-10-key-questionsand-answers.pdf. Accessed August 15, 2013.
23. Elliott RA, Majumdar SR, Gillick MR, et al. Benefits and consequences of the new Medicare drug benefit for the poor and the disabled. N Engl J Med. 2005;353:2739-2741.
24. Haviland AM, Elliott MN, Weech-Maldonado R, et al. Racial/ethnic disparities in Medicare Part D experiences. Med Care. 2012;50:S40-S47.
25. Briesacher BA, Zhao Y, Madden JM, et al. Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007. Med Care. 2011;49: 834-841.
26. Centers for Medicare and Medicaid Services. MSIS State Data Characteristics/Anomalies Report. Availbable at http://www.cms.gov/Research- Statistics-Data-and-Systems/Computer-Data-and-Systems/MedicaidData SourcesGenInfo/downloads/anomalies1.pdf. Accessed June 17, 2013
27. - 2005 Illinois Register: Rules of Governmental Agencies. 2005;29:12683-13064. Available at http://www.cyberdriveillinois.com/departments/ index/register/register-volume29-issue34.pdf. Accessed May 15, 2014.
28. Kentucky Cabinet for Health and Family Services. Department for Medicaid Services. Outpatient Pharmacy Programs. Available at: http://www.lrc.ky.gov/kar/ 907/001/019.htm. Accessed October 28, 2011.
29. Adams AS, Zhang F, LeCates RL, et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med. 2009;169:750-756.
30. Arday SL, Arday DR, Monroe S, et al. HCFAs racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev. 2000;21:107-116.
31. Agency for Healthcare Research and Quality, US Department of Health and Human Services. Creation of New Race-Ethnicity Codes and Socioeconomic Status (SES) Indicators for Medicare Beneficiaries, Final Report, January 2008. Prepared by: RTI International [CMS Contract Number: 500-00-0024, Task No. 21], AHRQ Publication Number 08-0029-EF.
32. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment for Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev. 2004;25:119-141.
33. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299-309.
34. Harper S, Lynch J, Meersman SC, et al. An overview of methods for monitoring social disparities in cancer with an example using trends in lunch cancer incidence by area-socioeconomic position and raceethnicity, 1992-2004. Am J Epidemiol. 2008;167:889-899.
35. Teixeira-Pinto A, Siddique J, Gibbons R, et al. Statistical approaches to modeling multiple outcomes in psychiatric studies. Psychiatr Ann. 2009;39:729-735.
36. SAS Institute Inc. SAS OnlineDoc, Version 9. SAS Institute Inc.: Cary, NC 2002-2006.
37. Basu A, Yin W, Alexander GC. Impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries prescription utilization and expenditures. Health Serv Res. 2010;45:133-151.
38. Shrank WH, Patrick AR, Pedan A, et al. The effect of transitioning to Medicare part d drug coverage in seniors dually eligible for Medicare and Medicaid. J Am Geriatr Soc. 2008;56:2304-2310.
39. Gamble VN. Under the shadow of Tuskegee: African Americans and health care. Am J Public Health. 1997;87:1773-1778.
40. Gellad WF, Huskamp HA, Phillips KA, et al. How the new Medicare drug benefit could affect vulnerable populations. Health Aff (Millwood). 2006;25:248-255.
41. Condliffe S, Link CR, Townsend B. Who receives statins? Variations in physicians prescribing patterns for patients with coronary heart disease, dyslipidemia, and diabetes. University of Delaware, Department of Economics; 2008. Working Paper 08-07. Available at: http://graduate. lerner.udel.edu/sites/ default/files/ECON/PDFs/RePEc/dlw/Working Papers/2008/UDWP2008-07.pdf. Accessed on May 15, 2014.